Six randomized controlled trials (RCTs)24,29,31,36,37,39, including a combined total of 372 patients, compared the mean difference in controlled attenuation parameter (CAP) among non-alcoholic fatty liver patients given SGLT-2 inhibitor or the control intervention (see Fig. 2a). This evidence concerns the gene SLC5A2 and fatty liver disease.